Atacicept is under clinical development by Vera Therapeutics and currently in Phase III for IgA Nephropathy (Berger’s Disease). According to GlobalData, Phase III drugs for IgA Nephropathy (Berger’s Disease) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Atacicept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Atacicept overview
Atacicept is under development for the treatment of persistent proteinuria and IgA nephropathy (Berger's disease). The drug candidate is administered by subcutaneous route in the form of solution. It is a new biological entity. Atacicept is a recombinant fusion protein, contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. It was also under development for the rheumatoid arthritis, multiple sclerosis (MS) and optic neuritis (ON), lupus nephritis, systemic lupus erythematosus (SLE).
See Also:
Vera Therapeutics overview
Vera Therapeutics is a biotechnology company that discovers and develops treatments for immunological diseases. It is investigating its lead product candidate Atacicept, a recombinant self-administered fusion protein to treat IgA nephropathy (IgAN) and lupus nephritis (LN). The company is also evaluating MAU868, a neutralizing antibody targeting BK viremia in renal transplant recipients and BKV cystitis in hematopoietic stem cell transplant (HSCT) recipients. Its product candidate targets B cells and plasma cells and reduces disease causing autoantibodies. Vera Therapeutics is headquartered in Brisbane, California, the US.
For a complete picture of Atacicept’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
